STUDY OF ACUTE TOXICITY OF NOVEL ANTITUMOR PREPARATION BASED ON DERIVATIVE OF INDOLOCARBAZOLE - LCS-1208
https://doi.org/10.17650/1726-9784-2015-14-4-59-64
Abstract
The research has been devoted to the study of acute toxicity of preparation based on derivative of indolocarba- zole - LCS-1208 in mice of both sexes and in rats of both sexes at intravenous and intraperitoneal administration of the drug. In the experiments the laboratory animals - outbred white rats and hybrid mice (C57Bl/6JxDBA2)Fl (B6D2F1) have been used. On the results of study has been obtained the calculated toxic doses of novel preparation based on derivative of indolocarbazole at intraperitoneal administration of the drug in mice of both sexes.
About the Authors
A. A. Nikolina
FSBI «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
N. Ju. Kul'bachevskaja
FSBI «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
O. I. Konjaeva
FSBI «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
V. A. Chalej
FSBI «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
N. P. Ermakova
FSBI «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
V. M. Bukhman
FSBI «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Патент №2548045 Российская Федерация, МПК С07Н 19/04, А61Р 35/00, А61К 31/7008. N-гликозиды индоло[2,3-а]пирроло[3,4-с]карбазолов, обладающие противоопухолевой активностью / Тихонова Н. И. , Ярцева И. В., Ерёмина В. А., Эктова Л. В. и др.; заявитель и патентообладатель - ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН. - № 2014107507; заявл. 21.02.14; опубл. 10.04.15, Бюл. № 10 - 13 с.
2. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ под ред. Р.У.Хабриев. - М.: Медицина, 2005. - 832 с.
3. Смирнова 3. С., Кубасова И. Ю., Борисова Л. М. Противоопухолевая активность N-гликозидов производных индоло[2,3-а]карбазола // Российский биотерапевтический журнал. - 2006. - Т. 5, №3. - С. 123-7.
4. Akinaga S., Sugiyama К., Акіуата Т. UCN-01 (7-hydroxy staurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for new century? // Anticancer Drug Des. - 2000. - 15. - P. 43-52.
5. Kaluzhny D.N, Tatarskiy V.V. Jr., Dezhenkova L.G. et al. Novel antitumor L-Arabinoze derivative of indolocarbazole with high affinity to DNA // Chem. Med. Chem. - 2009. - 4. - P. 1641-8.
6. Meng L.-H., Liao Z.Y., Pommier Y. Non-camptothecin DNK topoisomerase I inhibitors in cancer therapy // Curr. Top. Med. Chem. - 2003. - 3. - P. 305-20.
7. Pruhomme M. Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents // Curr. Med. Chem. - 2000. - 7. - P. 1189-1212.
8. Pruhomme M. Rebeccamycin analogues as anti-cancer agents // Eur. J. Med. Chem. - 2003. - 38. - P. 123- 40
9. Sanchez C„ Mendez C„ Salas J.A.J. Engineering biosynthetic pathways to generate antitumor indolocarbazole derivatives // Ind Microbiol Biotechnol. - 2006. - 5. - P. 560-8.
Review
For citations:
Nikolina A.A., Kul'bachevskaja N.J., Konjaeva O.I., Chalej V.A., Ermakova N.P., Bukhman V.M. STUDY OF ACUTE TOXICITY OF NOVEL ANTITUMOR PREPARATION BASED ON DERIVATIVE OF INDOLOCARBAZOLE - LCS-1208. Russian Journal of Biotherapy. 2015;14(4):59-64. (In Russ.) https://doi.org/10.17650/1726-9784-2015-14-4-59-64
Views:
313
Email this article 
